On September 29, 2022, the European Commission issued draft Implementing Decision that does not approve 2,2-Dibromo-2-cyanoacetamide (DBNPA) as an active substance for use in biocidal products of product-type 4. As stated in the draft decision, DBNPA has endocrine disrupting properties that may cause adverse effects in humans and the environment (non-target organisms). DBNPA therefore meets the exclusion criteria set out in Article 5(1), point (d), of Regulation (EU) No 528/2012. As alternatives are available for its use in biocidal products of product-type 4, it was therefore appropriate not to approve DBNPA for use in biocidal products of product-type 4 as per the decision. Public comments can be submitted till November 28, 2022.